Breast Cancer, Version 3.2013

View More View Less
  • 1 From The University of Texas MD Anderson Cancer Center; Stanford Cancer Institute; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; University of Washington/Seattle Cancer Care Alliance; Dana-Farber/Brigham and Women’s Cancer Center; Roswell Park Cancer Institute; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; University of Alabama at Birmingham Comprehensive Cancer Center; Fox Chase Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; University of Michigan Comprehensive Cancer Center; Memorial Sloan-Kettering Cancer Center; Massachusetts General Hospital Cancer Center; UCSF Helen Diller Family Comprehensive Cancer Center; Duke Cancer Institute; Vanderbilt-Ingram Cancer Center; UNMC Eppley Cancer Center at The Nebraska Medical Center; St. Jude Children‘s Research Hospital/The University of Tennessee Health Science Center; Research Advocacy Network; Moffitt Cancer Center; City of Hope Comprehensive Cancer Center; Huntsman Cancer Institute at the University of Utah; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; and National Comprehensive Cancer Network.
Restricted access

These NCCN Guidelines Insights highlight the important updates specific to the management of HER2-positive metastatic breast cancer in the 2013 version of the NCCN Clinical Practice Guidelines in Oncology for Breast Cancer. These include new first-line and subsequent therapy options for patients with HER2-positive metastatic breast cancer.

Supplementary Materials

    • Supplemental Material (PDF 178 KB)
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 658 261 28
PDF Downloads 118 50 5
EPUB Downloads 0 0 0